| Hanoun, Maher |
| Recruiting | 2 | 65 | Europe | Inotuzumab ozogamicin | Nicola Goekbuget, Pfizer Pharma GmbH | Precursor Cell Lymphoblastic Leukemia | 06/25 | 12/25 | | |
| Recruiting | 2 | 146 | Europe | Venetoclax plus Azacitidine, standard of care chemotherapy plus gemtuzumab ozogamicin | Technische Universität Dresden, University Hospital Heidelberg, AbbVie | Acute Myeloid Leukemia | 09/28 | 09/28 | | |
GMALL-BLIVEN, NCT05182385: Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) |
|
|
| Recruiting | 1/2 | 39 | Europe | Blinatumomab, blincyto, Venetoclax, Venclyxto | Goethe University, University Hospital Schleswig-Holstein | ALL, Recurrent, Adult | 06/25 | 12/25 | | |
| Active, not recruiting | 1/2 | 55 | Europe | Venetoclax Oral Tablet, Cytarabin | Technische Universität Dresden, AbbVie | Relapsed Adult AML, Refractory AML | 10/23 | 08/25 | | |
| Recruiting | 1/2 | 214 | Europe | MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO, Rydapt, Mylotarg, MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO, MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO, MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin, MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin | Technische Universität Dresden, Novartis Pharmaceuticals, Pfizer | Acute Myeloid Leukemia | 04/27 | 04/28 | | |
NCT03188874: Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL) |
|
|
| Recruiting | N/A | 15000 | Europe | | Technische Universität Dresden | Acute Myeloid Leukemia (AML) | 09/30 | 09/30 | | |
